FDA cited Age Management Institute Santa Barbara for insanitary sterile compounding of IV drugs, including dirty equipment and expired ingredients.
What happened
FDA inspected the facility from March 22 to April 12, 2021, and issued its inspection findings form (Form FDA 483). The investigator found sterile drug products were prepared, packed, or held under insanitary conditions, including no certified ISO 5 clean area, visibly dirty equipment and surfaces, a dirty air vent, carpet in the IV storage and mixing room, and a refrigerator with dripping and standing water touching sterile containers. FDA also said the firm distributed drug products made with expired components, and the firm stopped IV therapy production as of the inspection.
What FDA found
Sterile drug products were prepared under conditions that could contaminate them, which the law calls adulterated.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The facility did not have a certified ISO 5 classified area for sterile compounding.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Aseptic processing areas had equipment and surfaces that were visibly dirty and difficult to clean, including a hood with a dirty filter and stained, peeling paint.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]An air vent in the IV storage and mixing room was visibly dirty, and part of the floor was covered with carpet.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]A refrigerator with dripping and standing water on an inside shelf was used to store sterile drug products, and containers/closures touched the condensate water.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm distributed drug products prepared using expired components.
FDCA section 301(k) [21 U.S.C. § 331(k)]
What FDA wants
FDA asks the firm to reply in writing within 15 working days with steps taken to address the violations, or to state that it will not resume sterile drug production. If it plans to resume, FDA recommends a comprehensive assessment with a qualified third-party consultant and asks for 15 working days' notice before resuming.
Who should pay attention
- patients receiving compounded IV therapy
- clinics and physicians that buy or use compounded sterile drugs
- compounding pharmacies and sterile compounders
This is a summary. Read the original letter on fda.gov.